Table 1 Baseline characteristics table (N = 214)
N (%) or Median(min-max) | ||
|---|---|---|
Age (years) | 58 (26–81) | |
Gender | Male | 166 (77.6) |
Female | 48 (22.4) | |
Nephrectomy | No | 90 (42.1) |
Yes | 121 (56.5) | |
Unknown | 3 (1.4) | |
Treatment free interval | ≥1 yr | 56 (26.2) |
< 1 yr | 158 (73.8) | |
Anemia | Normal | 44 (20.6) |
Hb < 13.5/12.0 (M/F) | 170 (79.4) | |
Hypercalcemia | Normal | 180 (84.1) |
> 10 mg/dL or 2.5 mmol/L | 28 (13.1) | |
Unknown | 6 (2.8) | |
Neutrophilia | Normal | 174 (81.3) |
< 1500 or > 7500 | 33 (15.4) | |
Unknown | 7 (3.3) | |
Elevated LDH | Normal | 96 (44.9) |
>×1.5ULN | 49 (22.9) | |
unknown | 69 (32.2) | |
KPS | > 80 | 204 (95.3) |
≤ 80 | 4 (1.9) | |
unknown | 6 (2.8) | |
Thrombocytosis | Normal | 192 (89.7) |
> 400 K | 22 (10.3) | |
Therapy | Immunotherapy | 126 (58.9) |
Target Therapy | 88 (41.1) | |
Heng | Intermediate risk | 171 (79.9) |
Poor risk | 43 (20.1) | |
Tumor (T) | T1 - T2 | 96 (44.9) |
T3 -T4 | 61 (28.5) | |
Unknown | 57 (26.6) | |
Lymph node(N) | N0 | 54 (25.2) |
N1 | 45 (21.0) | |
Nx | 30 (14.0) | |
Unknown | 85 (39.7) | |
Metastasis | cM0 | 27 (12.6) |
cM1 | 81 (37.9) | |
pM1 | 2 (0.9) | |
cMx | 3 (1.4) | |
Unknown | 101 (47.2) | |
mRCC type | Synchronous mRCC | 144 (67.3) |
Metachronous mRCC | 70 (32.7) | |
Fuhrman nuclear grade | G1-G2 | 41 (19.2) |
G3-G4 | 101 (47.2) | |
Unknown | 72 (33.6) | |
Histology | Clear cell | 164 (76.6) |
Non-clear cell | 12 (5.6) | |
Unknown | 38 (17.8) | |
Treatment duration (Month) | 4.2 (1.0–70.4) | |
Follow-up duration (Month) | 98.3 (4.8–147.6) | |
Progression free survival (Month, median(95%CI)) | 4.7 (3.8–5.5) | |
Cancer-specific survival (Month, median(95%CI)) | 13.8 (9.8–18.3) | |
Cancer-specific survival status | Censored/ Event | 32 (15.0)/ 182 (85.0) |
Progression-free survival status | Censored/ Event | 21 (9.8)/ 193 (90.1) |